Fundraising FoxAlexandria — 2018 Investments
11 investments dated 2018 · listed companies and verified rows first · show all
Confluence Genetics (operating at bensonhillbio.com) is a seed innovation company that develops soybean genetics using AI-driven plant science and proprietary tools such as eMERGE Genetics and CropOS.
Durham, US
Matthew B Crisp(Executive Officer, Director)Lee Palles(Executive Officer)inNadine Carozzi(Executive Officer)Todd C Mockler(Executive Officer)Thomas Brutnell(Executive Officer)
BoardDaniel J Broderick(Director)
Co-investorsActivant CapitalBioGenerator VenturesCultivation CapitalFall Line CapitalGV (Google Ventures)iSelect Fund+6 more
BiotechCambridge, US
Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)
BoardNoubar B. Afeyan, Ph.D.(Director)
Co-investorsGV (Google Ventures)SV Health InvestorsFlagship PioneeringKaiser Permanente VenturesMayo Clinic Ventures
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersARCH Venture PartnersBering Capital+5 more
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)inLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSARCH Venture PartnersWRF Capital
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)in
Co-investorsEcoR1 CapitalPontifax Venture CapitalRA CapitalUS Venture PartnersNextech InvestOrbiMed
BiotechCambridge, US
James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)
BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)
Co-investorsLongitude CapitalLundbeckfonden VenturesNew Enterprise Associates (NEA)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Magnolia NeurosciencesNohla TherapeuticsPrevail TherapeuticsQuentis
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.